Boston Scientific (NYSE:BSX) Upgraded by Leerink Partnrs to “Strong-Buy” Rating

Leerink Partnrs upgraded shares of Boston Scientific (NYSE:BSX) to a strong-buy rating in a research note released on Monday morning,Zacks.com reports. Leerink Partnrs also issued estimates for Boston Scientific’s Q2 2025 earnings at $0.73 EPS, Q3 2025 earnings at $0.72 EPS, Q4 2025 earnings at $0.73 EPS, Q1 2026 earnings at $0.79 EPS, Q2 2026 earnings at $0.82 EPS, Q3 2026 earnings at $0.84 EPS, Q4 2026 earnings at $0.90 EPS, FY2026 earnings at $3.36 EPS and FY2027 earnings at $3.88 EPS.

Other equities research analysts also recently issued reports about the stock. Royal Bank of Canada increased their price objective on shares of Boston Scientific from $116.00 to $120.00 and gave the company an “outperform” rating in a research report on Thursday, April 24th. Argus set a $130.00 target price on shares of Boston Scientific in a research report on Tuesday, February 18th. Needham & Company LLC reaffirmed a “buy” rating and issued a $115.00 target price on shares of Boston Scientific in a research report on Wednesday, May 28th. Evercore ISI raised their price objective on shares of Boston Scientific from $110.00 to $112.00 and gave the stock an “outperform” rating in a research report on Thursday, April 24th. Finally, Citigroup restated a “buy” rating and issued a $125.00 target price (up previously from $119.00) on shares of Boston Scientific in a research note on Thursday, May 22nd. Twenty-two investment analysts have rated the stock with a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $116.09.

Boston Scientific Stock Performance

Shares of BSX stock opened at $101.49 on Monday. The firm’s 50 day moving average price is $101.25 and its 200-day moving average price is $98.87. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. Boston Scientific has a one year low of $71.88 and a one year high of $107.17. The firm has a market cap of $150.15 billion, a P/E ratio of 81.19, a P/E/G ratio of 2.79 and a beta of 0.68.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.08. The company had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The firm’s quarterly revenue was up 20.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.56 EPS. As a group, equities research analysts predict that Boston Scientific will post 2.85 EPS for the current year.

Insider Activity

In other Boston Scientific news, EVP John Bradley Sorenson sold 4,572 shares of the company’s stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $104.54, for a total transaction of $477,956.88. Following the completion of the sale, the executive vice president now directly owns 18,705 shares of the company’s stock, valued at approximately $1,955,420.70. This represents a 19.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Vance R. Brown sold 4,826 shares of the stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $95.09, for a total transaction of $458,904.34. Following the completion of the sale, the senior vice president now directly owns 36,193 shares of the company’s stock, valued at $3,441,592.37. This trade represents a 11.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 411,970 shares of company stock worth $42,406,693. Corporate insiders own 0.50% of the company’s stock.

Institutional Trading of Boston Scientific

A number of hedge funds have recently made changes to their positions in the stock. Parnassus Investments LLC lifted its position in shares of Boston Scientific by 0.7% in the fourth quarter. Parnassus Investments LLC now owns 14,861 shares of the medical equipment provider’s stock worth $1,327,000 after purchasing an additional 97 shares in the last quarter. HM Payson & Co. lifted its position in shares of Boston Scientific by 1.4% in the first quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider’s stock worth $694,000 after purchasing an additional 98 shares in the last quarter. Baldwin Investment Management LLC lifted its position in shares of Boston Scientific by 1.2% in the fourth quarter. Baldwin Investment Management LLC now owns 8,740 shares of the medical equipment provider’s stock worth $781,000 after purchasing an additional 102 shares in the last quarter. Park Square Financial Group LLC lifted its position in shares of Boston Scientific by 5.2% in the first quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider’s stock worth $208,000 after purchasing an additional 103 shares in the last quarter. Finally, HHM Wealth Advisors LLC lifted its position in shares of Boston Scientific by 13.2% in the first quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider’s stock worth $89,000 after purchasing an additional 103 shares in the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.